AMRX - Amneal stock falls 8% following Q4 results; FY22 EPS outlook seen below estimates

Amneal Pharmaceuticals (AMRX -8.3%) stock declined following its mixed Q4 results and and non-GAAP EPS guidance below estimates. Q4 revenue rose +5.27% Y/Y to $536.9M, beating estimates. The increase was driven by Generic new product launches and growth in the company's promoted Specialty products, including Rytary and Unithroid, partially offset by price erosion. Q4 adjusted net income rose +25.07% Y/Y to $54.22M. The non-GAAP EPS of $0.18 missed analysts' estimates. Gross profit declined -0.4% Y/Y to $166.40M. Net loss attributable to Amneal widened to -$6.38M, compared to -$3.04M in Q4 2020. Q4 adjusted EBITDA grew +17.65% Y/Y to $126.37M. Outlook 2022: The company expects full year net revenue to be in the range of $2.15B to $2.25B. Consensus Revenue Estimate for 2022 is $2.15B. Adjusted EPS is expected between $0.80 and $0.85. Consensus EPS Estimate for 2022 is $0.90. Adjusted EBITDA forecasted between $540M and $560M. Operating cash flow expected in the range of $225M to $250M. Capital expenditures

For further details see:

Amneal stock falls 8% following Q4 results; FY22 EPS outlook seen below estimates